Out-License, Co-Promote, or Solo-First launch? Insights From an Expert Panel and a Decade of U.S. and EU First-Launch and Partnering Data

2:15 PM - 3:15 PM (PDT), Monday, June 13, 2022 ・ Upper Level, Session Room 6F

A key question facing pre-commercial emerging pharma and biotech company leadership and directors is whether to co-promote or solo-launch for the first time rather than out-license an asset or seek a sale of the company. We will review first-launch and partnering data  for the last decade of U.S. and EU novel and 505b2 first launches. This will include partnering trends in the U.S., EU, and Asia as well as exit values post-launch for solo and co-promote launches in selected therapeutic areas. Our expert panel will discuss how they considered whether to commercialize for key regions and their learnings. We will also assess the over- or underperformance of U.S. solo and co-promote first launches vs. expectations for 2019 (pre-COVID), 2020, and 2021.    Participants considering whether to partner or commercialize will gain significant insights, valuable data, and expert guidance by attending this presentation and panel discussion.

Moderator
photo
Principal -- BD, Pipeline and Launch Strategy & Emerging Pharma Lead
ZS Associates
Speakers
photo
Former SVP, Global Commercial Operations & Market Access
Arena Pharmaceuticals, Inc.
photo
VP Business Development
Adaptimmune
photo
Head of Business Development and Strategic Advisor
BioLineRx, Ltd
photo
VP, Head of Commercial
Allogene Therapeutics